SynthesisMedicine2022
Hydromorphone vs sufentanil in patient-controlled analgesia for postoperative pain management: A meta-analysis.
Synthesis in Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Comparison of Oliceridine and Hydromorphone for Postoperative Analgesia in Adults Undergoing Lower Limb Fracture Surgery: A Randomized Controlled Non-Inferiority Trial.Drug design, development and therapy · 2026Trial
- Precision application of target-controlled infusion of esketamine combined with sufentanil in anesthesia for thoracoscopic surgery and its effect on hemodynamics, postoperative pain, and safety.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026Trial
- Comparison of different hydromorphone bolus doses in patient-controlled intravenous analgesia for post-laparoscopic surgery: a randomized controlled trial.BMC anesthesiology · 2025Trial
- Buccal Acupuncture Reduces the Dose of Sufentanil Needed in Laparoscopic Gynecological Surgery.Medical science monitor : international medical journal of experimental and clinical research · 2025Trial
- Effects of hydromorphone-based patient-controlled intravenous analgesia on postpartum depression after cesarean section: a prospective randomized controlled trial.Frontiers in medicine · 2025Trial
- Comparison between sufentanil and hydromorphone for postoperative analgesia after cesarean section: a propensity-score matched analysis.Frontiers in medicine · 2026Article
- Personalized Multimodal and Opioid-Sparing Analgesia for Postoperative Pain Management: Enhancing Recovery and Addressing the Post-Discharge Gap.Journal of pain research · 2026Review
- Effect of Intrathecal Hydromorphone on the Duration and Efficacy of Postoperative Analgesia in Patients Undergoing Benign Anorectal Surgery: Protocol for a Randomized, Double-Blind, Controlled Trial.Journal of pain research · 2026Article
- Hydromorphone ameliorates postoperative pain and depressive disorder in women receiving cesarean section under spinal anesthesia.Frontiers in medicine · 2025Article
- Efficacy and safety of hydromorphone for postoperative patient-controlled intravenous analgesia for patients undergoing orthopedic surgery: a randomized, double-blinded controlled trial.Frontiers in medicine · 2025Article
- International Pain Outcomes (IPO) - Brazilian Portuguese version: cross-cultural adaptation and psychometric validation.Revista brasileira de enfermagem · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatient-controlled analgesia (PCA) is an effective method of postoperative pain, there have been many studies performed that have compared the efficacy of hydromorphone with continuous sufentanil. The purpose of this systematic review is to compare the efficacy and safety of hydromorphone and sufentanil.
methodsSeven databases were searched for controlled trials to compare the efficacy and safety of hydromorphone and sufentanil. After selecting the studies, extracting the data, and assessing study quality, the meta-analysis was performed on several of the studies with RevMan 5.3.
resultsThirteen studies comprised of 812 patients were found. The pain intensity of the hydromorphone group was significantly lower than that of the sufentanil group at 12 hours. With no statistical difference at 24 to 48 hours (MD12 = -1.52, 95% CI [-2.13, -1.97], P <.05). The sedation intensity of the hydromorphone group at 12, 24, and 48 hours were lower than those of the sufentanil group, with no statistical difference (MD12 = -0.03, 95% CI [-0.18, 0.12], P > .05; MD24 = -0.20, 95% CI [-0.42, 0.03], P > .05; MD48 = -0.03, 95% CI [-0.18, 0.11)], P > .05). The PCA requests in the hydromorphone group were less than that in the sufentanil group, and there was no significant difference (RR = -0.20, 95% CI [-1.93,1.53], P > .05). The incidence of adverse events in the hydromorphone group was less than that in the sufentanil group, and there was a statistical difference: (RR = 0.61, 95% CI [0.47,0.79], P < .05).
conclusionCompared with sufentanil, PCA with hydromorphone was more effective in relieving pain and PCA requests 12, 24, and 48 hours after operation, and significantly reduced the incidence of adverse events, but it did not have an advantage in sedation intensity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.